{"schema_version":"secwatch.filing_event.v1","accession":"0001743881-25-000010","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.318532+00:00","generated_at":"2026-05-17T01:41:30.217957+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BridgeBio Q3 2025: $120.7M revenue, Attruby launch accelerating; positive Phase 3 data for BBP-418 and encaleret","bullets":["Total revenue $120.7M (Q3 2024: $2.7M), driven by $108.1M Attruby net product revenue.","Net loss $182.7M ($0.95/sh) vs $162.0M ($0.86/sh) in prior year; cash $645.9M.","Attruby: 5,259 prescriptions written by 1,355 prescribers since Nov 2024 approval.","BBP-418 Phase 3 met endpoints: glycosylated αDG increased 1.8x (p<0.0001); NDA filing planned 1H 2026.","Encaleret Phase 3 met primary endpoint: 76% achieved target calcium vs 4% on conventional (p<0.0001); NDA in 1H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001743881-25-000010","json":"https://secwatch.observer/filing/0001743881-25-000010.json","markdown":"https://secwatch.observer/filing/0001743881-25-000010.md","text":"https://secwatch.observer/filing/0001743881-25-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/0001743881-25-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20251029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:41:30.217957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}